Newly diagnosed and relapsed follicular lymphoma: EHA Clinical Practice Guidelines for diagnosis, treatment, and follow-up. (PubMed, Hemasphere) - Oct 24, 2026 - "For relapsed or refractory disease, treatment with Rituximab-Lenalidomide combination ± Tafasitamab or Epcoritamab from the first relapse and single-agent bispecific antibodies, chimeric antigen receptor T-cell therapy (CAR-T) cells, and Zanubrutinib-Obinutuzumab after second relapse should be prioritized over immunochemotherapy. Patients should be actively involved in decision-making. In this guideline, we present current evidence-based recommendations for diagnosis, staging, treatment, and follow-up."
Clinical guideline • Journal • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Oncology
|
|
Armando Lopez-Guillermo; Catherine Thieblemont; Ewa Paszkiewicz-Kozik; Franck Morschhauser; Guy Bouguet; Jessica Okosun; Judith Trotman; Kim Linton; Klaus Herfarth; Marco Ladetto; Marek Trneny; Martin Dreyling; Natacha Bolaños; Sanne Helene Tonino; Sirpa Leppa; Stefano Luminari; Umut Yilmaz; Wolfram Klapper
|